Varying oropharyngeal colostrum administration dosages on outcomes associated with very low birth weight infants: a
Yao Jin1,2, Zhenyan Fu3, Ji Jin3
1Nursing Department, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Insights
Oropharyngeal colostrum administration (OCA) shows potential benefits for very low birth weight infants (VLBWIs). This study investigates how different OCA doses impact clinical outcomes and immune markers in VLBWIs.
Area of Science:
- Neonatal immunology
- Pediatric critical care
Background:
- Oropharyngeal colostrum administration (OCA) offers immunological advantages to very low birth weight infants (VLBWIs).
- Variability in OCA protocols exists, with limited research on its effects on hematological indices and dose-dependent impacts.
- Investigating dose-response relationships is crucial for optimizing OCA therapy.
Purpose of the Study:
- To evaluate the efficacy of varying Oropharyngeal colostrum administration (OCA) dosages in very low birth weight infants (VLBWIs).
- To compare the incidence of major neonatal complications across different OCA treatment arms and a control group.
- To assess the impact of different OCA doses on key hematological and immunological markers.
Main Methods:
- A single-centre, three-arm, parallel-controlled randomized controlled trial enrolling 129 VLBWIs.
- Blinded design with participants randomized to receive 0.2 mL OCA every 3 or 6 hours for 10 days, or standard care.
- Primary endpoints include necrotizing enterocolitis, bronchopulmonary dysplasia, and retinopathy of prematurity; secondary endpoints assess immunological markers like IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ, and IgA.
Main Results:
- This section is to be filled once the study is completed and results are available.
Conclusions:
- This section is to be filled once the study is completed and results are available.
Introduction:
Oropharyngeal colostrum administration (OCA) confers immunological benefits to very low birth weight infants (VLBWIs) through nutrient absorption via oropharyngeal lymphatic tissue, potentially reducing complication rates and improving clinical outcomes. Current evidence demonstrates significant variability in OCA protocols regarding the initiation timing, application frequency, treatment duration and dosage of this therapy across studies, and limited research exists on its impact on haematological indices in infants. Notably, the dose-dependent effects of OCA on both clinical outcomes and haematological immunological parameters in VLBWIs remain insufficiently investigated. We hypothesise that varying OCA doses will demonstrate differential impacts on clinical outcomes and systemic levels of key immunological markers in VLBWIs.
Methods And Analysis:
This single-centre, three-arm, parallel-controlled randomised controlled trial will enrol 129 VLBWIs to evaluate the efficacy of OCA. Using a blinded design, both outcome assessors and data analysts will be masked to group allocation throughout the study. Participants will be randomly assigned in a 1:1:1 ratio into three groups: two receiving OCA (0.2 mL colostrum every 3 hours or 6 hours for 10 days) and a control group with standard care only. The primary endpoints of this trial are to compare the incidence of necrotising enterocolitis, bronchopulmonary dysplasia and retinopathy of prematurity across the three groups. Additionally, we will assess haematological and immunological indicators, including IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ and serotype immunoglobulin A levels, to evaluate the potential effects of different OCA dosages on these parameters.
Ethics And Dissemination:
This study protocol received full ethical approval (No. KLL-2023-505) from the ethics committee of the Affiliated Hospital of Zunyi Medical University on 5 September 2023, after a thorough review. The study findings will be disseminated through publication in peer-reviewed journals.
Trial Registration Number:
ChiCTR2300077114. Registration on 31 October 2023.
Related Concept Videos
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:01Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
01:26Enteral Nutrition I: Orogastric and Nasogastric Feeding
Orogastric (OG) and nasogastric (NG) feeding are two standard methods used for enteral nutrition. Enteral nutrition is often preferred over...
01:19One-Compartment Open Model for IV Bolus Administration: General Considerations
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...